Conditions Associated with Elevated Free Kappa Light Chains

Primary Plasma Cell Disorders

The International Myeloma Society recommends that multiple myeloma is the most common cause of elevated free kappa light chains when the kappa/lambda ratio is abnormal (>1.65), with the malignant plasma cell clone secreting unstable immunoglobulin light chains 1, 2
The American Society of Clinical Oncology states that light chain myeloma presents with elevated free light chains without heavy chain expression, representing a more aggressive variant 1
Smoldering multiple myeloma (SMM) demonstrates elevated free light chains with abnormal ratios but without end-organ damage, requiring close monitoring for progression, as recommended by the International Myeloma Working Group 1

The International Myeloma Working Group defines light chain MGUS by abnormal free light chain ratio with increased involved light chain, no heavy chain expression, <10% bone marrow plasma cells, and absence of end-organ damage 1
The condition has the lowest progression risk at only 0.27% per year, substantially lower than conventional MGUS at 1% per year, according to the National Comprehensive Cancer Network 1

The American College of Cardiology states that AL amyloidosis involves a slowly proliferating bone marrow plasma cell clone secreting unstable immunoglobulin free light chains that infiltrate peripheral organs (kidneys, heart, GI tract, liver, nervous system) causing organ dysfunction 2, 3
More than 69% of AL patients already have multiple organ involvement at diagnosis, making early detection critical, as recommended by the American Heart Association 2

The National Kidney Foundation states that renal impairment causes decreased clearance of both kappa and lambda free light chains, leading to elevation even with a normal kappa/lambda ratio (0.26-1.65) 1, 4
In severe renal impairment (CKD stage 5), the normal kappa/lambda ratio range expands to 0.34-3.10, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 4

The American Society of Clinical Oncology recommends performing serum protein electrophoresis (SPEP) and immunofixation (SIFE) to identify and quantify monoclonal proteins 4, 5
Obtain 24-hour urine collection for electrophoresis and immunofixation to assess urinary light chain excretion (Bence Jones protein), as recommended by the National Comprehensive Cancer Network 4, 5

The American Society of Clinical Oncology states that for light chain cast nephropathy, initiate bortezomib-containing regimens immediately to decrease production of nephrotoxic clonal immunoglobulin 1, 4
Bortezomib/dexamethasone can be administered without dose adjustment in severe renal impairment, according to the National Comprehensive Cancer Network 4
Provide adequate hydration and urine alkalinization, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 4
Avoid nephrotoxic medications such as NSAIDs in all patients with elevated light chains, as recommended by the American College of Rheumatology 4, 5

Serum protein electrophoresis (SPEP) with immunofixation should be performed to detect and characterize any abnormal monoclonal proteins in patients with abnormal free light‑chain results. 6
A 24‑hour urine collection (rather than a random or single‑spot sample) is required to quantify urinary light‑chain excretion; morning urine specimens are insufficient for this purpose. 6

Low‑dose computed tomography, positron‑emission tomography, or magnetic resonance imaging are recommended to evaluate for bone lesions or organ involvement when a plasma‑cell disorder is suspected. 7

Serial free‑light‑chain measurements must be interpreted together with other disease markers such as SPEP results and bone‑marrow assessments, because multiple myeloma can progress to a “light‑chain escape” phenotype that produces only light chains. 6
In patients with measurable urinary M‑protein, serum free‑light‑chain testing does not replace 24‑hour urine studies; both modalities provide complementary information for accurate disease monitoring. 6